<DOC>
	<DOC>NCT01857232</DOC>
	<brief_summary>Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy</brief_summary>
	<brief_title>Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<criteria>Inclusion criteria Male or female patients ≥ 18 years of age Ability and willingness to give written informed consent Patients scheduled to receive, on day 1 of their chemotherapy, either: (i) a first cisplatin chemotherapy infusion at a dose of ≥70 mg/m2 (males and females); or (ii) a first infusion of cyclophosphamide at a dose of 5001500 mg/m2 in combination with either epirubicin at a dose of 60100 mg/m2 or doxorubicin at a dose of 4060 mg/m2 (females only) Karnofsky performance score ≥ 60% Adequate cardiac, hepatic and renal function QTc interval &lt; 500 ms Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &lt; 5 x upper limit normal (ULN) Bilirubin &lt; 5 x ULN Creatinine &lt; 3 x ULN Adequate haematological function Haemoglobin ≥ 8 g/dL White blood count ≥ 3.0 x 109/L Platelet count ≥ 100 x 109/L For females of childbearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a doublebarrier method of contraception such as either an intrauterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) during the study and for a period of at least 48 hours afterwards Exclusion Criteria Patients scheduled to receive, prior to or in the 120 hours after cisplatin or AC, any other chemotherapeutic agent with a high or moderate emetic risk Patients who have previously received antineoplastic chemotherapy Patients scheduled to receive paclitaxel or docetaxel during the first cycle of their chemotherapy Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours after cisplatin or AC administration Patients with a known prolactindependent tumour (e.g. pituitary gland prolactinoma or confirmed prolactindependent breast cancer) or phaeochromocytoma Patients with a preexisting vestibular disorder Patients being treated with regular antiemetic therapy including corticosteroids Patients receiving inhaled corticosteroids, unless started more than one month prior to the expected date of study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>